Trial | NCT00669149  Report issue

Title

Anticoagulant Treatments and Percutaneous Coronary Angioplasty
Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    99
The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.
Background : We don't know if using IV anticoagulant therapy is necessary for percutaneous coronary angioplasty in stable patients.
Purpose : to compare efficacy and security of use or not of different anticoagulant treatments during percutaneous coronary angioplasty in patients with double antiaggregant therapy.
Abstract : In stable patients pretreated with double antiaggregant therapy use of IV anticoagulants has not been yet evaluated during angioplasty. In this prospective randomized trial we want to compare in such patients the efficacy and security of the administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant during coronary angioplasty. We will evaluate in each group ischaemic events (clinic, ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up.
Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post procedure.
Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht, TIMI score)
Study design : monocentric randomized clinical trial type therapeutic equivalence phase IV.
Interventions : In patients prepared with therapeutic association (aspirin clopidogrel) comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV bivalirudin).
Number of subjects : 120 per group (total of 480).
Statistical analysis : multivariate analysis with logistic regression models : each end point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment group and other covariates (sex, age, creatinine, …).
Study Started
Jun 30
2008
Primary Completion
Aug 03
2013
Study Completion
Aug 03
2013
Last Update
May 17
2019

Drug clopidogrel + aspirin

  • Other names: Plavix Kardégic

Drug heparin + clopidogrel + aspirin

  • Other names: héparine Choay Plavix Kardégic

Drug enoxaparin + clopidogrel + aspirin

  • Other names: Lovenox Plavix Kardégic

Drug bivalirudin + clopidogrel + aspirin

  • Other names: Angiox Plavix Kardégic

1 Experimental

group without anticoagulant therapy

2 Active Comparator

group with heparin

3 Active Comparator

group with enoxaparin

4 Active Comparator

group with bivalirudin

Criteria 

Inclusion Criteria:

stable angina pectoris or silent ischaemia

Exclusion Criteria:

instable angina or ACS (Acute Coronary Syndrome)
No Results Posted